A Phase 1/2 interventional study of PRL3-ZUMAB and Normal Saline (0.9% Sodium Chloride) in Neovascular Age Related Macular Degeneration, sponsored by Intra-IMMUSG Pte Ltd. Recruiting at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Intra-IMMUSG Pte Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Macular Degeneration with a site in Singapore — 6 open to participants now, 10 under way, 2 of them phase 3. Macular Degeneration · Singapore.
Among the 24 studies in Macular Degeneration with a site in Singapore, this one is the 18th largest by planned enrollment of the 18 interventional ones that give a count, is one of 7 that started in 2025, is the only one in phase 1/2, and was the 23rd registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →6 of the 24 studies in Macular Degeneration with a site in Singapore are open now. Recruiting first, the newest first:
Singapore National Eye Centre · Sites in Singapore
Ages 55+
4D Molecular Therapeutics · Sites in Singapore, United States, Argentina and 14 more countries
Ages 50+
Singapore National Eye Centre · Sites in Singapore
Ages 50+
Tan Tock Seng Hospital · Sites in Singapore
Ages 50–99
Tan Tock Seng Hospital · Sites in Singapore
Ages 55–99
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 327 across the 18 interventional studies, 139 across the 6 observational. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 24 have an industry lead sponsor. The 10 most frequent:
Intra-IMMUSG Pte Ltd is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Intra-IMMUSG Pte Ltd has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
6 of the studies in Macular Degeneration with a site in Singapore that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT06518512Tan Tock Seng HospitalAutomated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients | 2026-12 |
| NCT07547228Intra-IMMUSG Pte LtdA Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) | 2027-02-07 |
| NCT07338513Tan Tock Seng HospitalUser-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 24 studies in Macular Degeneration with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD).
PRL3-zumab will be administered intravenously in 2-week interval for 3 doses. Normal saline (0.9% Sodium Chloride w/v) will be used in placebo treatment. The study will consist of 3 arms.
Arm-1: PRL3-zumab 3mg/kg intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-2: PRL3-zumab 6mg/kg intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-3: Placebo (normal saline 0.9% sodium chloride w/v) intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=3)
Initial 3 arms will be conducted on patients who failed Standard-of-Care (SOC) therapy. Response assessment will be done at every 4 weeks from last dose of treatment till 24-week.
Randomization:
Randomization will be done in 2:2:1 manner on PRL3-zumab (Arm 1), 3mg/kg (n=6); PRL3-zumab (Arm 2), 6mg/kg (n=6); and placebo group (Arm 3) (n=3). Randomization can be achieved using random number table which will be prepared before the commencement of clinical trial.
The allocation of participants will be done by Investigator and will be concealed from the participants.
Blinding:
Single blinding will be done for this trial in which all participants are unaware of their treatment assignment. No blinding will be done on Investigator.
Primary Endpoints:
Safety:
RP2D:
Efficacy:
[Assessment Time Frame: 4 weekly through 24 weeks]
Secondary endpoints:
Criteria for additional Therapy:
Once the treatment is stopped after the third dose, patients from all groups are eligible for additional therapy as open-label treatment if there is recurrence of disease activity, as defined by presence of any of the following criteria:
Patients in the placebo group will be given PRL3-zumab (6mg/kg) if they fulfil the criteria for additional therapy. Additional therapy will be continued in subsequent monitoring visit until the progression of disease, or end of the trial. If patients show clinical benefit from the treatment, additional doses could be given based on investigators' judgment.
Criteria for progression of disease:
ASSESSMENTS:
Safety:
All adverse events (AEs) will be classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 or the latest version.
Treatment-emergent adverse events (TEAEs), Treatment-related TRAEs, serious TEAEs, TEAE of Grade 2 or greater, TEAEs leading to treatment discontinuation, and TEAEs leading to dose modification will be summarized respectively. Physical examination findings, Clinical laboratory data, vital signs will be summarized descriptively.
. Ocular adverse event:
Ocular adverse events will be identified at every drug administration visit followed by every 4 weeks (28 days) eye examination. Any ocular adverse events will be recorded and determined for possible or probable relation to study treatment. Post-injection complications including worsening visual acuity, change in vision, worsening macular oedema, vitreous hemorrhage, retinal pigment epithelium tears, retinal tear or detachments, inflammation and intra ocular pressure (IOP) alterations will be identified.
Efficacy:
Efficacy assessment will be performed 4 weeks from the first dose of treatment by
DURATION OF THE STUDY:
The duration of study treatment is 4 weeks and monitoring is 20 weeks. Total duration of study will be 24 weeks.
Treatment Period:
PRL3-zumab will be administered 3 times in 2-week interval within the first 4 weeks of study period. Treatment with be terminated in case of intolerable toxicity, patients meet the criteria for end-of-trial or withdrawal of consent.
Monitoring Period:
Monitoring will be done every 4 weeks, starting from 4 weeks after the 3rd dose of study medication. The total duration of Monitoring period will be 20 weeks (All 3 arms). The trial will be terminated in case of intolerable toxicity, patients meet criteria for end of trial or withdrawal of consent.
Sample Size Determination PRL3-zumab was administered intravenously with the dose of 6mg/kg in > 155 advanced cancer patients to date (14 Dec 2023) with no safety issue. No drug-related Serious Adverse Event was reported so far. This clinical trial is for extended indication of PRL3-zumab in nAMD disease.
Primary endpoint is adverse events, visual acuity, central retinal thickness and IRF and/or SRF. No. of evaluable patients for primary endpoint (minimum) in each cohort = 3 -6 Only patients who have received PRL3-ZUMAB are evaluable, patients who did not receive PRL3-ZUMAB may be replaced to achieve the total sample size.
Arm 1: PRL3-zumab 3mg/kg (n=6) Arm 2: PRL3-zumab 6mg/kg (n=6) Arm 3: Placebo (normal saline) (n=3)
Once the Recommended Phase 2 Dose (RP2D) is confirmed and endpoints have been assessed in this trial, this protocol will be amended to include a detailed design of a Phase II expanded study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants receiving intravitreal treatment at screening must complete a before enrolment. This wash-out period should be calculated based on five half-lives of the specific intravitreal treatment the participant is receiving.
Below is the washing out period for some standard of care treatments.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: PRL3-ZUMAB
Biological: PRL3-ZUMAB
Other: Normal Saline (0.9% Sodium Chloride)
The study will consist of 3 arms, PRL3-zumab 3mg/kg, 6mg/kg and placebo. PRL3-zumab will be administered intravenously in 2-week interval for 3 doses.
Placebo group will be administered with normal saline, administered intravenously in 2-week interval for 3 doses.
Safety: Adverse Events according to CTCAE
Frequency and severity of adverse events throughout the primary outcome assessment period will be assessed by the Investigator for severity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 or later.
Time frame: 24 weeks
Recommended Phase 2 Dose (PR2D)
This study will confirm RP2D established from Phase I Clinical Trial conducted in National University Hospital (NUH) Singapore in Cancer patients (MC/03/0616).
Time frame: 24 weeks
Efficacy: Best Corrected Visual Acuity (BCVA) measured by ETDRS letter score
Change From Baseline in Best Corrected Visual Acuity (BCVA) measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score will be monitored. Change in BCVA letter gains of 0-4 will be considered as primary outcome measure.
Time frame: 24 weeks
Efficacy: Subfield Retinal Thickness (CST) measured by Optical Coherence Tomography (OCT)
Change from Baseline in Central Subfield Retinal Thickness (CST) measured by Optical Coherence Tomography (OCT) will be monitored
Time frame: 24 weeks
Best Corrected Visual Acuity (BCVA) measured by ETDRS letter score
Change in Best Corrected Visual Acuity (BCVA) of 5 or more letters measured by ETDRS letter score will be considered as secondary end point. Proportion of patients gaining ≥15, ≥10, ≥5, or ≥0 of ETDRS letters in BCVA from baseline over time will be monitored. Proportion of patients avoiding a loss of ≥15, ≥10, or ≥5 ETDRS letters in BCVA from baseline over time will be monitored
Time frame: 24 weeks
Intraretinal fluid measured by Optical Coherence Tomography (OCT)
Proportion of patients with absence of intraretinal fluid measured by Optical Coherence Tomography (OCT) will be monitored
Time frame: 24 weeks
Subretinal fluid measured by Optical Coherence Tomography (OCT)
Proportion of patients with absence of subretinal fluid measured by Optical Coherence Tomography (OCT) will be monitored
Time frame: 24 weeks
Plan to share: Undecided
Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.
Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-PRL-3 Monoclonal Antibody PRL3-zumab
Intra-IMMUSG Pte Ltd